This company listing is no longer active
OKYO Pharma Management
Management criteria checks 1/4
Key information
Gary Jacob
Chief executive officer
UK£1.5m
Total compensation
| CEO salary percentage | 17.5% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.05% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?
Nov 26
Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?
Jan 27Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation
Sep 22We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth
Mar 17We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow
Dec 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -UK£7m |
| Jun 30 2022 | n/a | n/a | -UK£5m |
| Mar 31 2022 | UK£1m | UK£256k | -UK£4m |
| Dec 31 2021 | n/a | n/a | -UK£4m |
| Sep 30 2021 | n/a | n/a | -UK£4m |
| Jun 30 2021 | n/a | n/a | -UK£3m |
| Mar 31 2021 | UK£649k | UK£61k | -UK£3m |
Compensation vs Market: Gary's total compensation ($USD1.82M) is above average for companies of similar size in the UK market ($USD352.33K).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
CEO
Gary Jacob (75 yo)
2.3yrs
Tenure
UK£1,467,000
Compensation
Dr. Gary S. Jacob, PhD, served as an Independent Director at Virpax Pharmaceuticals, Inc. since April 2020 until July 25, 2022. He had been an Independent Director of Cardiff Oncology, Inc. since February...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.3yrs | UK£1.47m | 0.049% £ 11.4k | |
| Founder | no data | no data | no data | |
| Chief Financial Officer | 2.8yrs | no data | 0% £ 0 | |
| Chief Scientific Officer | 2.2yrs | no data | 0% £ 0 |
2.3yrs
Average Tenure
64yo
Average Age
Experienced Management: OKYO's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.3yrs | UK£1.47m | 0.049% £ 11.4k | |
| Independent Non-Executive Director | 1.4yrs | UK£14.00k | no data | |
| Non-Executive Chairman | 2.3yrs | UK£120.00k | 33.47% £ 7.8m | |
| Independent Non-Executive Director | 2.9yrs | UK£55.00k | 0% £ 0 | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Senior Independent Non-Executive Director | 7.5yrs | UK£35.00k | 0.019% £ 4.3k | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.3yrs
Average Tenure
71yo
Average Age
Experienced Board: OKYO's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.